摘要:
The present invention provides a method for the design and/or the selection of agonist or antagonist chemokine variants combining a phage display technology and a screening on living cells expressing the receptor of the corresponding native chemokine. It also provides RANTES variants having agonist properties towards said receptor, and methods for preventing and/or curing viral diseases, as well as clues for preventing and/or curing inflammatory or malignant diseases.
摘要:
Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a liver-expressed chemokine (LEC). In one embodiment, the cancer targeting molecule is an antibody that targets cancer cells or tumors in vivo. The cancer targeting molecule is associated non-covalently or covalently with LEC. The cancer therapeutic agents of the invention are useful for the treatment of cancer in an individual by reducing the size of a tumor or inhibiting the growth of cancer cells in an individual and/or by inhibiting the development of metastasis. The effectiveness of the therapy using the LEC cancer therapeutic agents can be increased by reducing the activity of immunoregulatory T cells and/or by adoptively transferring immune T cells.
摘要:
The present invention provides methods of discovering and mapping secondary binding sites on biological molecules (e.g., proteins), the effects, if any, of site occupancy on the primary function of the molecule, and the screening of small molecules against the secondary binding sites. The invention further provides novel complexes for modification of secondary binding sites and the resulting modified biological molecules.
摘要:
The present invention provides a cDNA encoding a heretofore unknown polypeptide termed canine CYP1A2; the canine CYP1A2 polypeptide encoded by the gene; antibodies to the polypeptide; and methods of making and using all of the foregoing.
摘要:
The present invention relates to purified polynucleotides and a composition comprising a plurality of polynucleotide probes that are modulated in response to cytokines and which are associated with human immune response, conditions, disorders, and diseases. The present invention presents methods for using the polynucleotides, and use of the polynucleotide probes as hybridizable elements in a microarray.
摘要:
The present invention relates to a novel hematopoietic signaling factor (HSF) protein which is a member of the cytokine superfamily. In particular, isolated nucleic acid molecules are provided encoding the human HSF protein. HSF polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same.
摘要:
The present invention relates to a polypeptide having preferably antitumoral and/or immunomodulating cytokine properties, which can be activated by processing in vivo comprising a central region with specific biological activity. At its C-terminus said region has a region with a processing unit and an inhibitor domain, while at the N-terminus of the central region, there is a region that selectively recognizes a macromolecule on a cell surface or a component of the extracellular matrix.
摘要:
Novel NEOKINE polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length NEOKINE proteins, the invention further provides isolated NEOKINE fusion proteins, antigenic peptides and anti-NEOKINE antibodies. The invention also provides NEOKINE nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a NEOKINE gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
摘要:
A compound comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage is described.
摘要:
The invention provides a family of antibodies that specifically bind the human epithelial cell adhesion molecule. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a human. The antibodies, when coupled to the appropriate moiety, may be used in the diagnosis, prognosis and treatment of cancer.